真实世界环境下 EGFR 突变型肺癌女性患者中酪氨酸激酶抑制剂的疗效：WORLD07 数据库。

Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database.

机构信息

Medical Oncology Department, Hospital Vall d'Hebron, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain.

Medical Oncology Department, Instituto de Investigación Sanitaria Aragón, Hospital Clinico Universitario Lozano Blesa, Saragossa, Spain.

出版信息

Clin Transl Oncol. 2017 Dec;19(12):1537-1542. doi: 10.1007/s12094-017-1700-8. Epub 2017 Jun 28.

DOI:10.1007/s12094-017-1700-8

PMID:28660482

Abstract

BACKGROUND

The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer.

METHODS

WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) were selected for this analysis.

RESULTS

From October 2007 to December 2012, a total of 1775 NSCLC women were recruited. EGFR mutation was identified in 34.4% of patients. Upfront EGFR tyrosine kinase inhibitor (TKI) reported a response rate of 60%, a median progression-free survival of 11.7 months, and median overall survival of 23.0 months. EGFR TKI, EGFR-mutation type, and smoking status did not impact in the outcome of treated women.

CONCLUSION

Prevalence of EGFR mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported.

摘要

背景

WORLD07 项目是一个专门针对女性肺癌患者特征的数据库。

方法

WORLD07 数据库于 2007 年建立，前瞻性地存储了肺癌女性患者的临床特征、治疗、结局和随访情况。本分析中选择了所有表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）女性患者。

结果

从 2007 年 10 月至 2012 年 12 月，共招募了 1775 名 NSCLC 女性患者。34.4%的患者存在 EGFR 突变。一线 EGFR 酪氨酸激酶抑制剂（TKI）治疗的缓解率为 60%，中位无进展生存期为 11.7 个月，中位总生存期为 23.0 个月。EGFR TKI、EGFR 突变类型和吸烟状况对治疗女性患者的结局没有影响。